US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Assembly Biosciences, Inc. - Common Stock
(NQ:
ASMB
)
23.53
+0.71 (+3.11%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Assembly Biosciences, Inc. - Common Stock
< Previous
1
2
3
Next >
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
October 05, 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
September 10, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
September 08, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
August 13, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Upcoming Investor Conference Presentations
May 28, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 26, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
May 22, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
May 22, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
May 13, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
May 11, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
May 07, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
April 09, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
March 19, 2026
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
November 10, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
November 07, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Upcoming Investor Conference Participation
October 14, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
October 10, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
August 08, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
August 08, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
August 06, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
August 06, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
July 26, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
June 30, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
June 25, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
May 27, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
May 08, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
May 07, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
April 09, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
March 20, 2025
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
